Bringing Psoriasis into the Light, Kim kjoeller, Leo Pharma
•
2 j'aime•3,881 vues
The document discusses psoriasis, a chronic skin condition affecting over 125 million people worldwide. Psoriasis causes thickened, red, scaly skin patches that often itch and bleed. It can also cause joint pain and increase risks for other health issues. The document outlines pharmaceutical company efforts to develop new drug treatments for psoriasis, including topical treatments, biologics, and oral medications currently in clinical trials. It emphasizes the need for comprehensive care that coordinates treatment from specialists and considers patients' needs to best manage psoriasis as a chronic condition.
Recommandé
Recommandé
Contenu connexe
Tendances
Tendances (20)
En vedette
En vedette (19)
Similaire à Bringing Psoriasis into the Light, Kim kjoeller, Leo Pharma
Similaire à Bringing Psoriasis into the Light, Kim kjoeller, Leo Pharma (20)
Plus de International Federation of Pharmaceutical Manufacturers & Associations (IFPMA)
Plus de International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) (16)
Dernier
Dernier (20)
Bringing Psoriasis into the Light, Kim kjoeller, Leo Pharma
- 1. Bringing psoriasis into the light Geneva Pharma Forum 9 May 2014 Kim Kjøller, Senior Vice President, Global Development, LEO Pharma 14 May 2014 p. 01
- 2. Psoriasis: A chronic, non- communicable disease affecting over 125 million people worldwide Psoriasis appears on the skin, most often as thickened, red, scaly patches that often itch and may bleed. It is a non-contagious, chronic, inflammatory disease that can be both painful and disabling.ii More people with psoriasis need better access to the medical care and appropriate solutions for either their psoriasis or for the psychosocial issues they may face as a result of their psoriasis.ii People with psoriasis report feeling embarrassed and helpless due to their condition.ii 14 May, 2014 p. 02 Picture: Nestle FO et al. N Engl J Med 2009;361:496-509 i "Facts about Psoriasis." Ed. Catie Coman. National Psoriasis Foundation, 2012. Web. 19 Dec. 2012. <http://www.psoriasis.org/document.doc?id=1492>. ii "Psoriasis and Mental Health Issue Brief." National Psoriasis Foundation, Jan. 2012. Web. 11 Dec. 2012 <http://www.psoriasis.org/document.doc?id=350>.
- 3. People with severe psoriasis die four years younger, on average, than people without the disease. iii As many as 30% of people with psoriasis will be diagnosed with psoriatic arthritis, a specific form of arthritis that is painful and debilitating and causes joint damage.ii Psoriasis increases the risk of developing diabetes, independent of factors such as weight, hypertension and high cholesterol.iv One study showed that psoriasis patients have a 44% increased risk of suicidal thoughts, suicide attempts or completed suicides compared to the general population.v Another study showed that almost 10% of psoriasis patients surveyed reported a wish to be dead.vi Burden of Disease How psoriasis affects patients iii Gelfand JM, et al. Arch of Dermatol. 2007 Dec;143(12):1493-9. iv Neimann AL, et al. J Am Acad Dermatol. 2006;55(5):829-35. vKurd Sk, et al. Arch of Dermatol. 2010 Aug:146(8)891-5. vi Gupta MA, Gupta AK. Br J Dermatol 1998;139:846-50.
- 4. Psoriasis Pipeline Projects Topicals p. 04 14 May, 2014 Phase 1 Phase 2 Phase 3 Pre-registration AN-2898 Anacor Pharmaceuticals LP-001-09 LAILA Pharmaceuticals Pc4 Case Western Reserve University BYK-321084 Takeda Pharma SHP-141 Shape Pharmaceuticals ENN-01 Ennar Pharrma SOM-0606 Ennar Pharrma BCT194 Novartis Aganirsen Gene Signal AN-2728 Anacor Pharmaceuticals Apo805K1 ApoPharma BFH-772 Novartis CT-327 Creabilis Cyclosporine Advancell DPS-151 DermsPsor E-6201 Eisai IDP 118 Valeant LAS-41004 Almirall PH 10 IMCOR Ruxolitinib Incyte Corp Tofacitinib Pfizer Valrubicin Valderm Nia-114 Niadyne Pharma Clobetasol proprionate Foamix AKVANO Lipidor DLX-105 Delenex Therapeutics AS-101 BioMasAuranofin Viralytics MOL4249 Moleculin DD 25 Fortuderm Triamcinolone acetonide Nuvo Research Methotrexate MediQuest Betamethasone Valerate 0.12% Foamix TU-2100 Tammarking AM-001 DermAct Benvitimod Stiefel Pefcalcitol Maruho Tacrolimus Novaliq DFD01 Promius Pharma Ulobetasol Therapeutics Unknown formulation Spray/Foam Microemulsion Lotion Cream Ointment Gel 4 - 6 years to market 2 - 4 years to market 1 year to market Tazarotene + betamethasone Chongging Huapont Pharma *Source: Cortellis and ADIS
- 5. Psoriasis Pipeline Projects Biologics 14 May 2014 p. 05 Phase 1 Phase 2 Phase 3 Pre-registration BTT-1023 BioTie Therapies CJM Novartis AGM-811 Amgen BI-655066 Boehringer Ingelheim 18C3 X-Biotech AbGn-168 AbGenomics Intravenous Subcutaneous Injectable ASKP1240 Astellas Pharma Tregalizumab AbbVie Guselkumab Janssen Biotech IMO-3100 Idera Pharmaceuticals Inecalcitol Hybrigenics IMO-8400 Idera Pharmaceuticals 4 - 6 years to market 3 - 4 years to market 1 year to market Brodalumab Amgen Inc Ixekizumab Eli Lilly & Co. KHK-4827 Amgen Tildrakizumab Schering-Plough Corp/Merck Secukinumab Novartis Etanercept Biosimilar Sandoz *Source: Cortellis and ADIS Adalimumab Biosimilar Sandoz
- 6. Psoriasis Pipeline Projects Orals 14 May 2014 p. 06 Phase 1 Phase 2 Phase 3 Pre-registration 4 - 6 years to market 2 - 4 years to market 1 year to market *Source: Cortellis and ADIS Otezla® (Apremilast) Celgene CM-2489 TorreyPines/CalciMedica CT-1578 Cell Theraputics PRX-167700 Proximagen Group Trichuris suis ova Coronado Biosciences XP-23829 Xenoport Inc. Aminopterin Syntrix Biosystems ASP 015K Astellas Pharma Dimethyl fumarate Forward Pharma Baricitinib Incyte Corp/Eli LillyPonesimod Actelion Ltd SRT 2104 Sirtris Pharma, a GSK company VB-201 VBL Therapeutics Erlotinib OSI Pharmaceuticals CH-1504 Chelsea Therapeutics FX-125L Boehringer Ingelheim HBP-347 Hy BioPharma MT-1303 Mitsubishi Tanabe Pharma INCB-039110 Incyte Corp LLL 3348 Lupin CF-101 Can-Fite BioPharma Tofacitinib Pfizer LAS 41008 Almirall Voclosporin Aurina Pharmaceuticals Inecalcitol Hybrigenics
- 7. 14 May 2014 p. 07 “A strong programmatic and multidisciplinary approach to disease management that includes the coordination of care with specialists and other health care professionals, as well as consideration of patients’ needs and preferences are central to the management of all non-communicable diseases including psoriasis.” - WHO Psoriasis Report, 2013 Giving patients control of their disease
- 8. We go beyond products to offer complete care solutions • Patient support services empowers people to take control of their skin condition • Our care offerings aim to deliver precise and personalised information to patients – across all therapy areas
- 9. Data collection What gaps do we need to fill? 14 May, 2014 p. 09 Example of interactive disease atlas
- 10. WHO Psoriasis Resolution 14 May 2014 p. 010 The goal of getting the WHO psoriasis resolution adopted is a necessary challenge that must be met in order to create a better environment for psoriasis patients to lessen the stigma and discrimination they endure.